日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Correction: Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography

更正:应用对比增强超声评估阿特珠单抗联合贝伐珠单抗治疗肝细胞癌的效果

Uchikawa, Shinsuke; Kawaoka, Tomokazu; Fujino, Hatsue; Ono, Atsushi; Nakahara, Takashi; Murakami, Eisuke; Yamauchi, Masami; Miki, Daiki; Imamura, Michio; Aikata, Hiroshi

HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice

携带前核心区和基础核心启动子突变的乙型肝炎病毒(HBV)表现出高复制表型,并在人源化肝嵌合小鼠中引起内质网应激介导的细胞死亡。

Uchida, Takuro; Imamura, Michio; Hayes, C Nelson; Suehiro, Yosuke; Teraoka, Yuji; Ohya, Kazuki; Aikata, Hiroshi; Abe-Chayama, Hiromi; Ishida, Yuji; Tateno, Chise; Hara, Yuichi; Hino, Keisuke; Okamoto, Toru; Matsuura, Yoshiharu; Aizaki, Hideki; Wake, Kenjiro; Kohara, Michinori; Liang, T Jake; Oka, Shiro; Chayama, Kazuaki

Association of Hepatobiliary Phase of Gadoxetic-Acid-Enhanced MRI Imaging with Immune Microenvironment and Response to Atezolizumab Plus Bevacizumab Treatment

钆塞酸增强磁共振成像肝胆期与免疫微环境及阿特珠单抗联合贝伐珠单抗治疗反应的相关性

Tamura, Yosuke; Ono, Atsushi; Nakahara, Hikaru; Hayes, Clair Nelson; Fujii, Yasutoshi; Zhang, Peiyi; Yamauchi, Masami; Uchikawa, Shinsuke; Teraoka, Yuji; Uchida, Takuro; Fujino, Hatsue; Nakahara, Takashi; Murakami, Eisuke; Tsuge, Masataka; Serikawa, Masahiro; Miki, Daiki; Kawaoka, Tomokazu; Okamoto, Wataru; Imamura, Michio; Nakamura, Yuko; Awai, Kazuo; Kobayashi, Tsuyoshi; Ohdan, Hideki; Fujita, Masashi; Nakagawa, Hidewaki; Chayama, Kazuaki; Aikata, Hiroshi; Oka, Shiro

Modeling suggests that virion production cycles within individual cells is key to understanding acute hepatitis B virus infection kinetics

模型显示,单个细胞内的病毒颗粒产生周期是理解急性乙型肝炎病毒感染动力学的关键。

Hailegiorgis, Atesmachew; Ishida, Yuji; Collier, Nicholson; Imamura, Michio; Shi, Zhenzhen; Reinharz, Vladimir; Tsuge, Masataka; Barash, Danny; Hiraga, Nobuhiko; Yokomichi, Hiroshi; Tateno, Chise; Ozik, Jonathan; Uprichard, Susan L; Chayama, Kazuaki; Dahari, Harel

Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study

过渡到新的MAFLD分类对非B、非C型肝细胞癌的影响和实用性:一项回顾性队列研究

Johira, Yusuke; Nakahara, Takashi; Kinami, Takahiro; Yamasaki, Shintaro; Kosaka, Masanari; Shirane, Yuki; Miura, Ryoichi; Murakami, Serami; Yano, Shigeki; Amioka, Kei; Naruto, Kensuke; Ando, Yuwa; Kosaka, Yumi; Kodama, Kenichiro; Uchikawa, Shinsuke; Fujino, Hatsue; Ono, Atsushi; Murakami, Eisuke; Okamoto, Wataru; Yamauchi, Masami; Kawaoka, Tomokazu; Hayes, C Nelson; Tsuge, Masataka; Imamura, Michio; Aikata, Hiroshi; Oka, Shiro

Efficacy and safety of lenvatinib-transcatheter arterial chemoembolisation sequential therapy followed by surgical resection for intermediate-stage hepatocellular carcinoma beyond Up-to-7 criteria: a study protocol for a multicentre, single-arm, prospective study

乐伐替尼联合经导管动脉化疗栓塞术序贯治疗后行手术切除治疗超出Up-to-7标准的中期肝细胞癌的疗效和安全性:一项多中心、单臂、前瞻性研究的研究方案

Oshita, Ko; Kobayashi, Tsuyoshi; Namba, Yosuke; Fukuhara, Sotaro; Matsubara, Keiso; Takei, Daisuke; Nakano, Ryosuke; Okamoto, Wataru; Sakai, Hiroshi; Tanimine, Naoki; Nakahara, Takashi; Kuroda, Shintaro; Tahara, Hiroyuki; Ohira, Masahiro; Kawaoka, Tomokazu; Ide, Kentaro; Imamura, Michio; Aikata, Hiroshi; Ohdan, Hideki

Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma

乐伐替尼通过抑制晚期肝细胞癌肿瘤微环境中的免疫抑制细胞浸润来激活抗肿瘤免疫。

Yamauchi, Masami; Ono, Atsushi; Amioka, Kei; Fujii, Yasutoshi; Nakahara, Hikaru; Teraoka, Yuji; Uchikawa, Shinsuke; Fujino, Hatsue; Nakahara, Takashi; Murakami, Eisuke; Okamoto, Wataru; Miki, Daiki; Kawaoka, Tomokazu; Tsuge, Masataka; Imamura, Michio; Hayes, C Nelson; Ohishi, Waka; Kishi, Takeshi; Kimura, Mizuki; Suzuki, Natsumi; Arihiro, Koji; Aikata, Hiroshi; Chayama, Kazuaki; Oka, Shiro

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma

不可切除肝细胞癌患者对乐伐替尼的生存率和疗效分析

Amioka, Kei; Kawaoka, Tomokazu; Kosaka, Masanari; Johira, Yusuke; Shirane, Yuki; Miura, Ryoichi; Murakami, Serami; Yano, Shigeki; Naruto, Kensuke; Ando, Yuwa; Kosaka, Yumi; Fujii, Yasutoshi; Kodama, Kenichiro; Uchikawa, Shinsuke; Fujino, Hatsue; Ono, Atsushi; Nakahara, Takashi; Murakami, Eisuke; Okamoto, Wataru; Yamauchi, Masami; Imamura, Michio; Mori, Nami; Takaki, Shintaro; Tsuji, Keiji; Masaki, Keiichi; Honda, Yoji; Kouno, Hirotaka; Kohno, Hiroshi; Moriya, Takashi; Naeshiro, Noriaki; Nonaka, Michihiro; Hyogo, Hideyuki; Aisaka, Yasuyuki; Azakami, Takahiro; Hiramatsu, Akira; Aikata, Hiroshi

Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors

日本各类实体瘤患者接受免疫检查点抑制剂治疗后免疫相关不良事件的发生率及抗肿瘤疗效

Yoshikawa, Yuki; Imamura, Michio; Yamauchi, Masami; Hayes, C Nelson; Aikata, Hiroshi; Okamoto, Wataru; Miyata, Yoshihiro; Okada, Morihito; Hattori, Noboru; Sugiyama, Kazuhiko; Yoshioka, Yukio; Toratani, Shigeaki; Takechi, Masaaki; Ichinohe, Tatsuo; Ueda, Tsutomu; Takeno, Sachio; Kobayashi, Tsuyoshi; Ohdan, Hideki; Teishima, Jun; Hide, Michihiro; Nagata, Yasushi; Kudo, Yoshiki; Iida, Koji; Chayama, Kazuaki

The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment

在乐伐替尼治疗中,通过生物电阻抗分析进行体成分评估对晚期肝细胞癌患者的重要性

Yamaoka, Kenji; Kodama, Kenichiro; Kawaoka, Tomokazu; Kosaka, Masanari; Johira, Yusuke; Shirane, Yuki; Miura, Ryoichi; Yano, Shigeki; Murakami, Serami; Amioka, Kei; Naruto, Kensuke; Ando, Yuwa; Kosaka, Yumi; Uchikawa, Shinsuke; Uchida, Takuro; Fujino, Hatsue; Nakahara, Takashi; Murakami, Eisuke; Okamoto, Wataru; Yamauchi, Masami; Miki, Daiki; Imamura, Michio; Takahashi, Shoichi; Nagao, Akiko; Chayama, Kazuaki; Aikata, Hiroshi